Type 1 diabetes is one of the most common metabolic diseases in children and adolescents. A diagnosis of type 1 diabetes is a considerable burden for those affected and their families – especially when they are young. Further development of drug-based insulin and immunomodulatory therapies and increasing advances in technology mean that ever more innovative treatment options are available to achieve internationally defined target values. The most modern therapy currently available is the coupling of sensor system, control algorithm and insulin pump, the AID system (automated insulin delivery).
Autoren
- Dr. med. Jantje Weiskorn
- Dr. med. Felix Reschke
- Dr. med. Thekla von dem Berge
- Dr. med. Mareike Niemeyer
- PD Dr. med. Torben Biester
Publikation
- Pädiatrie-Special
Related Topics
You May Also Like
- Pathophysiological mechanisms and therapeutic perspectives
Metabolic syndrome in patients with schizophrenia
- Hand eczema: from diagnosis to treatment
Implementing sustainable, stage-appropriate measures
- Cystic fibrosis
Small spray – big footprint
- From symptom to diagnosis
Abdominal pain – Gastric outlet stenosis
- When the bones become more fragile: “Case Finding”
Fracture risk reduction in osteoporosis
- Biologics for plaque psoriasis
What increases the chance of a sustained remission?
- Pain and autism
Hurdles to pain treatment for autistic patients
- Findings from the ALS Symposium 2024 in Montreal